Poxvirus Used to Fight Cancer: Malignant Human Brain Tumors Cured in Mice


A cross-Canada scientific collaboration has successfully tested a potent new cancer-fighting virus that eliminates malignant brain tumors and prolongs survival in mice with a single injection.

The scientists from Calgary and London, Ontario have shown for the first time that myxoma virus, a poxvirus, will kill human brain tumors in mice and prolong the animals survival. Their findings were published this month in the journal Cancer Research.

Were extremely encouraged by these results and the apparent cure seen in the mice treated with the active virus compared to untreated mice or those injected with inactivated virus, says virologist Grant McFadden, a scientist at Robarts Research Institute in London and Canada research chair in molecular virology. His research on poxviruses over the past two decades has shed significant light on how viruses disarm their hosts immune systems and their potency as anti-cancer and anti-inflammatory agents.

For the brain tumor experiments, McFadden teamed up with Dr. Peter Forsyth of the University of Calgary, a professor in the departments of oncology, and biochemistry and molecular biology, who has developed a mouse model with human gliomas, a malignant form of brain tumor. Over the past two years, their laboratories have tested the virus against experimental models of human malignant tumors, both in cell culture and in living animals. Injecting the tumor with the virus was not only well-tolerated with only minimal inflammation at the site of the inoculation but 92 per cent of the 13 mice treated were alive and apparently cured when the experiment was finished (after more than 130 days).

Those animals continued to show a selective and long-lived myxoma virus infection in the tumors themselves but that infection did not spread and harm the animal, says Forsyth, director, Clark H. Smith Integrative Brain Tumour Research Centre. This and other factors suggest that myxoma virus warrants further investigation as a potential treatment for malignant brain tumors in people.

The University of Ottawa also played a major role: Dr. John Bell initiated the Canadian Oncolytic Virus Consortium, a program funded by The Terry Fox Foundation, to study various viruses with the potential to treat cancer. In 2004, Bell brought together the teams from London and Calgary to initiate the study reported in Cancer Research.

McFadden and Forsyth are now planning to test the virus as a treatment for a deadly melanoma that is known to spread to the lung. They will be able to tag the virus with a fluorescent protein and track its progress in mice as it attacks the metastasized tumor cells.

Oncolytic viruses are a particularly exciting weapon emerging in the fight against cancer, McFadden adds. There is a lot more preclinical work ahead but the next step is to learn how best to harness their potency and their potential.

Source: Robarts Research Institute




Related Videos
Jill Holdsworth, MS, CIC, FAPIC, CRCST, NREMT, CHL
Jill Holdsworth, MS, CIC, FAPIC, CRCSR, NREMT, CHL, and Katie Belski, BSHCA, CRCST, CHL, CIS
Baby visiting a pediatric facility  (Adobe Stock 448959249 by Rawpixel.com)
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Picture at AORN’s International Surgical Conference & Expo 2024
Infection Control Today and Contagion are collaborating for Rare Disease Month.
Related Content